Investor Relations NEWS

2012.04.23 Holiday closure of ReproCELL headquarters

ReproCELL headquarters in Japan closes on the dates below, for Japanese spring holiday season. April 30th May 3rd, 4th US subsidiary and UK office won’t be affected, and will be operating as usual.

2012.01.14 Headquarters moved

ReproCELL headquarters has moved to a new address. KDX Shin-Yokohama 381 Bldg. 9F 3-8-11,Shin-Yokohama, Kohoku-ku, Yokohama Kanagawa 222-0033, Japan The new office is located on the different floor of the same building as the previous one.

2011.12.18 ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes – Expected Launch in Q2 2012

YOKOHAMA, Japan, December 15, 2011 – ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company licensed worldwide right to commercialize hepatocytes derived from human iPS (induced pluripotent stem) cells. ReproCELL has been collaborating with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan) to establish an effective in-vitro drug screening for hepatic toxicity and liver metabolism using hepatocytes derived from human iPS cells since early this year. Together with NIBIO, the company successfully established the hepatocytes which highly express active drug metabolizing enzyme. Currently, the company is evaluating the system using various drugs with pharmaceutical companies to observe how the drugs are metabolized. ReproCELL […]

2011.01.05 ReproCELL to Enter Collaborative R&D on Human iPS Cell Derived Hepatocytes

ReproCELL announces today that it will start a collaboration with the National Institute of Biomedical Innovation (NIBIO) to develop human iPS cell-derived hepatocytes for in vitro drug screening, hepatic toxocity and drug metabolism. See the news

2010.09.01 ReproCELL announces new line of products in neuronal research using human iPS cells

Since April 2009, ReproCELL has been manufacturing iPS cell-derived cardiomyocytes for drug toxicity testing as the world’s first drug discovery support business provider founded on iPS cells. The prospective new offering of neuronal cells is the second line of products to be introduced by the company, and is a considerable expansion of their scope of business. ReproCELL will be the first in the world to offer iPS cell derived neuronal cells, and, more specifically, will provide dopaminergic neurons, motor neurons, and cerebral nerves.

2009.04.30 Cellartis and ReproCELL Sign Agreement to Provide CardioToxicity screening service using hESC derived Cardiomyocytes

Cellartis AB, a premier provider of stem cell derived products and technologies, and ReproCELL, a Japanese biotechnology company on the forefront of stem cell platforms and screening solutions, have today signed an agreement whereby ReproCELL can commercialise its QTempo Cardiotoxicity platform using beating human embryonic stem cell (hESC) derived Cardiomyocytes from Cellartis on a fee for service basis. In this first of a kind deal, cardiotoxicity testing via the ReproCELL QTempo platform will be commercially available using live and beating hESC derived cardiomyocytes to provide more accurate models of in vivo physiology. It is expected that the QTempo platform will emerge as the next generation solution to commercial hERG screening, […]

2009.04.16 New Stem Cell Technology to Improve Drug Safety

iPS cardiomyocytes used in a novel cardiotoxicity assay Drug side effects are a major problem for the drug industry. Even very rare events, when serious enough, can warrant drug withdrawal. Unfortunately, until a drug has been used by thousands of patients, these rare events can be impossible to predict. Identifying drugs that can trigger heart attacks before they reach the clinic is a major focus of ReproCELL. Current tests, especially at early stages of drug development, tend to focus on one aspect of heart cell function – the hERG ion channel. But there are a whole range of other ion channels, as well as other possible issues, which hERG tests […]